Health3 days ago
BofA Securities Initiates ‘Buy’ Rating for Supernus Pharmaceuticals
BofA Securities has initiated coverage of Supernus Pharmaceuticals (ticker: SUPN) with a “buy” rating, citing the market’s undervaluation of the company’s portfolio of central nervous system...
